MES for future-proof biomanufacturing

Abstract

The biopharmaceutical industry is at the forefront of healthcare innovation, delivering groundbreaking therapies like monoclonal antibodies (mAbs), cell and gene therapies, and vaccines that are delivering critical outcomes for patients.

This white paper provides a comprehensive overview of biomanufacturing challenges today, particularly in adopting and optimizing Manufacturing Execution Systems (MES). By exploring current limitations, emerging trends, and real-world case studies, the white paper provides leaders of biopharmaceutical organizations, Contract Development and Manufacturing Organizations (CDMOs), and Contract Research Organizations (CROs) with a guide for modernizing and optimizing their manufacturing operations.

Also, the white paper provides a prospective view on the future of MES, including advanced capabilities like artificial intelligence (AI), cloud integration, and predictive analytics. By understanding these developments, industry leaders can make more informed decisions about digitalizing their manufacturing processes and operating models.